Search

Displaying results 5391 - 5400 of 10000 in total
  1. Drug

    FP-1096

    go.drugbank.com/drugs/DB05310
    Experimental

    FP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.

  2. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease).

  3. Drug

    Canis lupus familiaris skin

    go.drugbank.com/drugs/DB10409
    Approved

    Canis lupus familiaris skin allergenic extract is used in allergenic testing.

  4. Drug

    Cedar oil

    go.drugbank.com/drugs/DB10917
    Approved

    Cedar oil (Juniperus virginiana) allergenic extract is used in allergenic testing.

  5. Drug

    Tivantinib

    go.drugbank.com/drugs/DB12200
    Investigational

    Tivantinib has been investigated in Solid Tumors.

  6. Drug

    Isatin

    go.drugbank.com/drugs/DB02095
    Experimental

    Isatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids. … The compound is found in many plants and Schiff bases of Isatin are have been investigated for pharmaceutical applications.

  7. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients

  8. Drug

    Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14390
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14393
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB14394
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.